ELAC2 and benign prostatic hyperplasia: The Ala541Thr variant led to reduced ELAC2 activity that resulted in impaired mitochondrial and nuclear tRNA processing and validated the role of ELAC2 [50], causing prostate hyperplasia and inflammation with age, but not prostate cancer [61].